To provide this transparent and efficient market, the ASE has implemented internationally recognized directives regarding market divisions and listing criteria.
A recent review of controlled oat tolerance studies indicated only one documented avenin-sensitive enteropathy (ASE) in 165, placing the risk of ASE at 0.6% of coeliac disease population.